Literature DB >> 25517855

Deletion of exon 1 of the SLC16A2 gene: a common occurrence in patients with Allan-Herndon-Dudley syndrome.

Benilde García-de Teresa1, Ariadna González-Del Angel, Miriam Erandi Reyna-Fabián, María de la Luz Ruiz-Reyes, Raúl Calzada-León, Bernardo Pérez-Enríquez, Miguel Angel Alcántara-Ortigoza.   

Abstract

BACKGROUND: Allan-Herndon-Dudley syndrome (AHDS) is an X-linked type of mental retardation resulting from hindered thyroid hormone access to neurons. Clustered nonrecurrent deletions of SLC16A2 exon 1 have been described in three patients with AHDS. We report a fourth patient with such a deletion and discuss possible mechanisms leading to these rearrangements. CASE
PRESENTATION: A three-and-a-half-year-old male with clinical and biochemical AHDS phenotype and a history of normal neonatal screening for hypothyroidism underwent SLC16A2 molecular analysis. Unexpectedly, he showed skeletal signs of hypothyroidism. METHODS AND
RESULTS: The exons of the SLC16A2 (MCT8) gene and the sequences surrounding exon 1 were amplified using PCR. The patient had a 36-kb deletion affecting exon 1 of SLC16A2. The deletion junction was subjected to bioinformatic analyses, along with two other reported exon 1 deletion junctions, identifying possible sequence features and mechanisms responsible for such genomic rearrangements. DISCUSSION/
CONCLUSION: This patient had a classic AHDS phenotype with an unexpectedly large anterior fontanel and delayed bone age and dentition. Bioinformatic analyses suggested that exon 1 deletions in patients with AHDS are caused by microhomology-mediated replicative-based and nonhomologous end-joining mechanisms. Rearrangement susceptibility may be due to the size of intron 1 and the percentage of repeat sequences.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25517855     DOI: 10.1089/thy.2014.0284

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  3 in total

Review 1.  Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias.

Authors:  Giacomo Garone; Alessandro Capuano; Lorena Travaglini; Federica Graziola; Fabrizia Stregapede; Ginevra Zanni; Federico Vigevano; Enrico Bertini; Francesco Nicita
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

Review 2.  Monocarboxylate Transporter 8 Deficiency: From Pathophysiological Understanding to Therapy Development.

Authors:  Ferdy S van Geest; Nilhan Gunhanlar; Stefan Groeneweg; W Edward Visser
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

3.  An Essential Physiological Role for MCT8 in Bone in Male Mice.

Authors:  Victoria D Leitch; Caterina Di Cosmo; Xiao-Hui Liao; Sam O'Boy; Thomas M Galliford; Holly Evans; Peter I Croucher; Alan Boyde; Alexandra Dumitrescu; Roy E Weiss; Samuel Refetoff; Graham R Williams; J H Duncan Bassett
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.